Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2003, Vol. 1 ›› Issue (2): 151-154.doi: 10.3736/jcim20030221

Previous Articles     Next Articles

Evidence-based medicine and treatment of lung cancer

Zhen-ye Xu()   

  1. Department of Tumor, Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 20032,China
  • Received:2003-01-09 Online:2003-06-20 Published:2018-10-19

Traditional Chinese medicine (TCM) thinks highly of Zheng Hou in the treatment of lung cancer. Zheng is evidence. Hou is clinical manifestations. After obtaining information and evidence of patients by means of the four diagnostic methods, doctors treat patients by syndrome differentiation. In TCM, the collection and study of medical literature of tumor are emphasized. Medical classics and successful treatment of certain cases are used to guide clinical treatment. Such practice of TCM is similar to that of evidence-based medicine (EBM). Oncology of TCM and EBM are all of ancient origin. There are many clinical reports of satisfactory curative effects in treating lung cancer by TCM. But there are still many problems in methodology, such as careless random method, incomparability in base line, and deficiency of large exponent, multicenter, blind method or randomization. Sometimes the effects of control drugs are incredible. The determination of near effect is not strict. There are exponent errors in statistics of near effect (CR+PR). Certainly, treatment of lung cancer by TCM has its uniqueness. The main characteristic of treatment by TCM is that it can restrain or slow the growth of tumor. At the same time, physical signs, symptoms and quality of life can be improved, and survival period is prolonged. "Survival rate is the golden standard". If we can explore a new treatment strategy to control the growth and metastasis of advanced NSCLC and prevent relapse and metastasis of earlier period or metaphase NSCLC by the method of binding TCM and west medicine under the rules of EBM, such as multicenter (TCM hospital and western medicine hospital),blind method, strict randomization and control, the conclusion of the study will be more scientific.

Key words: evidence-based medicine, lung cancer, therapeutics, traditional Chinese medicine

CLC Number: 

  • R242
[1] Cox JD, Azarnia N, Byhardt RW , et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11[J]. J Clin Oncol, 1990,8(9):1543-1555
doi: 10.1200/JCO.1990.8.9.1543
[2] Sandler HM, Curran WJ Jr, Turrisi AT 3rd . The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 1990,19(1):9-13
doi: 10.1016/0360-3016(90)90127-6
[3] Dosoretz DE, Galmarini D, Rubenstein JH , et al. Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication[J]. Int J Radiat Oncol Biol Phys, 1993,27(3):507-516
doi: 10.1016/0360-3016(93)90373-4
[4] Sawyer TE, Bonner JA, Gould PM , et al. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks[J]. Ann Thorac Surg, 1997, 64(5):1402-1407; discussion, 1407-1408
[5] Mayer R, Smolle-Juettner FM, Szolar D , et al. Post-operative radiotherapy in radically resected non-small cell lung cancer[J]. Chest, 1997,112(4):954-959
doi: 10.1378/chest.112.4.954 pmid: 9377958
[6] The Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stageⅡand stage Ⅲ epidermoid cancer of the lung[J]. N Engl J Med, 1986,315(22):1377-1381
[7] Stephens RJ, Girling DJ, Bleehen NM , et al. The role of postoperative radiotherapy in non-small cell lung cancer: a multicenter randomized trial in patients with pathologically staged T1-2,N1-2,M0 disease[J]. Br J Cancer, 1996,74(4):632-639
doi: 10.1038/bjc.1996.413
[8] 钱浩, 蒋国梁, 王丽娟 , 等. 非小细胞肺癌术后放疗511例分析[J]. 中华放射肿瘤学杂志, 1993,2(4):235-237
[9] 王瑞芝, 李明淑, 邓晓芹 , 等. 非小细胞肺癌不同治疗方法分析[J]. 中华放射肿瘤学杂志, 1995,4(1):34-36
[10] Liberati A. The potential and limitations of evidence-based medicine[A]. In: Asco Educational Book[M]. 1998. 446-450.
[11] 吴一龙 . 肺癌临床研究的方式、方法、方向[J]. 医学与哲学, 2000,21(3):1-5
doi: 10.3969/j.issn.1002-0772.2000.03.001
[12] 赖世隆, 胡镜清, 郭新峰 . 循证医学与中医药临床研究[J]. 广州中医药大学学报, 2000,17(1):1-8
doi: 10.3969/j.issn.1007-3213.2000.01.001
[13] 陈可翼, 宋军 . 循证医学的提出对中西医结合的启发[J]. 中国中西医结合杂志, 1999,19(11):643-644
doi: 10.3321/j.issn:1003-5370.1999.11.001
[14] 沙慧芳, 苏建中, 包国良, 等. 小鼠Lewis肺癌耐药细胞株的逆转研究[A]. 见: 中国肿瘤耐药与肿瘤化疗研究进展 (全国肿瘤耐药与肿瘤化疗药物应用学术会议论文汇编)[C]. 2001. 149.
[1] Wan-jun Guo, Yi Wang, Yu Deng, Lin-yan Cheng, Xin Liu, Ruo-fan Xi, Sheng-jie Zhu, Xin-yi Feng, Liang Hua, Kan Ze, Jian-yong Zhu, Dong-jie Guo, Fu-lun Li. Therapeutic effects of the extract of Sancao Formula, a Chinese herbal compound, on imiquimod-induced psoriasis via cysteine-rich protein 61. Journal of Integrative Medicine, 2022, 20(4): 376-384.
[2] Shang-jin Song, Xuan Liu, Qing Ji, Da-zhi Sun, Li-juan Xiu, Jing-yu Xu, Xiao-qiang Yue. Ziyin Huatan Recipe, a Chinese herbal compound, inhibits migration and invasion of gastric cancer by upregulating RUNX3 expression. Journal of Integrative Medicine, 2022, 20(4): 355-364.
[3] Marisa Casal. Improving the health and treatment success rates of in vitro fertilization patients with traditional chinese medicine: need for more robust evidence and innovative approaches. Journal of Integrative Medicine, 2022, 20(3): 187-192.
[4] Ning Guo, Fei Wu, Mei Wu, Yuan Wang, Qing Lang, Xiao Lin, Yi Feng. Progress in the design and quality control of placeboes for clinical trials of traditional Chinese medicine . Journal of Integrative Medicine, 2022, 20(3): 204-212.
[5] Yan-jun Lin, Kun-li Jiao, Bo Liu, Lu Fang, Shu Meng. Antiplatelet and myocardial protective effect of shexiang tongxin dropping pill in patients undergoing percutaneous coronary intervention: A randomized controlled trial. Journal of Integrative Medicine, 2022, 20(2): 126-134.
[6] Jia-jia Li, Qing Liang, Guang-chun Sun. Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: A focus on epithelial-mesenchymal transition. Journal of Integrative Medicine, 2021, 19(6): 469-477.
[7] Rui-jin Qiu, Min Li, Jia-yuan Hu, Jing Chen, Hong-cai Shang. Methods for development of a core outcome set for clinical trials integrating traditional Chinese medicine and Western medicine. Journal of Integrative Medicine, 2021, 19(5): 389-394.
[8] Mao-xing Pan, Chui-yang Zheng, Yuan-jun Deng, Kai-rui Tang, Huan Nie, Ji-qian Xie, Dong-dong Liu, Gui-fang Tu, Qin-he Yang, Yu-pei Zhang. Hepatic protective effects of Shenling Baizhu powder, a herbal compound, against inflammatory damage via TLR4/NLRP3 signalling pathway in rats with nonalcoholic fatty liver disease . Journal of Integrative Medicine, 2021, 19(5): 428-438.
[9] Ning Zhang, Xiao-he Xiao. Integrative medicine in the era of cancer immunotherapy: Challenges and opportunities. Journal of Integrative Medicine, 2021, 19(4): 291-294.
[10] Thomas Efferth, An-long Xu, Roxana Damiescu, Mita Banerjee, Norbert W. Paul, David Y.W. Lee. Can eastern wisdom resolve western epidemics? Traditional chinese medicine therapies and the opioid crisis. Journal of Integrative Medicine, 2021, 19(4): 295-299.
[11] Si-qi Tang, Yun-liang Wang, Zi-ye Xie, Yang Zhang, Yi Guo, Kang-li Gao, Tang-you Mao, Chun-e Xie, Jun-xiang Li, Xiao-yan Gao. Serum metabolic profiling of traditional Chinese medicine syndromes in patients with diarrhea-predominant irritable bowel syndrome. Journal of Integrative Medicine, 2021, 19(3): 274-281.
[12] Miao-yan Shi, Shi-qi Sun, Wei Zhang, Xing Zhang, Gui-hua Xu, Xuan Chen, Zi-jian Su, Xiu-ming Song, Lu-jiong Liu, Yi-bao Zhang, Yi-le Zhang, Meng Sun, Qi Chen, Yan Xue, Hua Lü, Wei-an Yuan, Xiao-rong Chen, Yun-fei Lu. Early therapeutic interventions of traditional Chinese medicine in COVID-19 patients: a retrospective cohort study. Journal of Integrative Medicine, 2021, 19(3): 226-231.
[13] Shu-jun Wei, Qing-man He, Qing Zhang, Kang-hua Fu, Ruo-lan Li, Wei Peng, Yong-xiang Gao. Traditional Chinese medicine is a useful and promising alternative strategy for treatment of Sjogren's syndrome: A review. Journal of Integrative Medicine, 2021, 19(3): 191-202.
[14] Yi Xia, Lu-shao-bo Shi, Jing-hui Chang, Hua-zhang Miao, Dong Wang. Impact of the COVID-19 pandemic on intention to use traditional Chinese medicine: A cross-sectional study based on the theory of planned behavior. Journal of Integrative Medicine, 2021, 19(3): 219-225.
[15] Na Zhi, Qian Mo, Shuo Yang, Yuan-xing Qin, Hao Chen, Zeng-guang Wu, Cai-hong Lan, Jun Zhang, Yin-long Li. Treatment of pulmonary fibrosis in one convalescent patient with corona virus disease 2019 by oral traditional Chinese medicine decoction: A case report. Journal of Integrative Medicine, 2021, 19(2): 185-190.
Full text



[1] Yi-ting He, Qing-lin Zha, Jian-ping Yu, Yong Tan, Cheng Lu, Ai-ping Lv. Principal factor analysis of symptoms of rheumatoid arthritis and their correlations with efficacy of traditional Chinese medicine and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 32-36
[2] Jun Cai, Hua Wang, Sheng Zhou, Bin Wu, Hua-rong Song, Zheng-rong Xuan. Effect of Sijunzi Decoction and enteral nutrition on T-cell subsets and nutritional status in patients with gastric cancer after operation: A randomized controlled trial. Journal of Chinese Integrative Medicine, 2008, 6(1): 37-40
[3] Wei Zhang, Xiang-feng Lu, Xiao-mei Zhang, Jian-jun Wu, Liang-duo Jiang. A rat model of pulmonary fibrosis induced by infusing bleomycin quickly through tracheal intubation. Journal of Chinese Integrative Medicine, 2008, 6(1): 60-67
[4] A-gao Zhou, Yong Zhang, Gang Kui, De-Yun Kong, Hai-liang Ge, Qiu-hua Ren, Jia-rong Dong, Sheng Hong, Xu-ming Mao, Yin Wang, Hui-zheng Zhang, Shu-jun Wang. Influence of traditional Chinese compound recipes with different efficacy on body weight, tumor weight and immune function in H22 cancer-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 77-82
[5] Guo-hong Yuan, Xiao-jing Pang, He-chao Ma. Synergic effects of Danggui Buxue Decoction in reducing toxicity of cytoxan in tumor-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 83-88
[6] Li Zhou, Hong-xing Zhang, Ling-guang Liu, Wen-jun Wan. Effect of electro-acupuncture at Fenglong (GV 16) on nitric oxide and endothelin in rats with hyperlipidemia. Journal of Chinese Integrative Medicine, 2008, 6(1): 89-92
[7] Jin-zhou Tian, Jing Shi, Xin-qing Zhang, Qi Bi, Xin Ma, Zhi-liang Wang, Xiao-bin Li, Shu-li Shen, Lin Li, Zhen-yun Wu, Li-yan Fang, Xiao-dong Zhao, Ying-chun Miao, Peng-wen Wang, Ying Ren, Jun-xiang Yin, Yong-yan Wang, Beijing United Study Group on MCI of the Capital Foundation of Medical Developments. Guiding principles of clinical research on mild cognitive impairment (protocol). Journal of Chinese Integrative Medicine, 2008, 6(1): 9-14
[8] Xin-jun Wang, Ling-ling Wang . A mechanism of endogenous opioid peptides for rapid onset of acupuncture effect in treatment of depression. Journal of Chinese Integrative Medicine, 2010, 8(11): 1014-1017
[9] Bo Wang , Wei Yan , Li-hui Hou, Xiao-ke Wu. Disorder of Tiangui (kidney essence) and reproductive dysfunction in patients with polycystic ovary syndrome. Journal of Chinese Integrative Medicine, 2010, 8(11): 1018-1022
[10] Bing Hu , Hong-mei An , Ke-ping Shen , Qin Du. Senescence-inducing effects of Chinese herbal medicine Tenglong Buzhong Decoction on human colon carcinoma LS-174-T cells and the mechanism. Journal of Chinese Integrative Medicine, 2010, 8(11): 1048-1052